The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that highlights the growing role of Asian biotech firms, Hong Kong-listed Metis TechBio has signed a licensing deal with U.S.-based Boulevard Bio. Under the agreement, Metis grants exclusive global rights to develop, manufacture and commercialize its experimental autoimmune drug MTS-128, in a deal worth up to $1.6 billion, according to Reuters.
The deal comes at a time of heightened interest in the autoimmune disease space. Boulevard Bio gains a promising candidate for its pipeline, while Metis secures up to $1.6 billion in milestone payments. Though the upfront payment was not disclosed, the agreement validates Metis's drug design platform and could attract further partnerships.
Sign in to access this content
Sign InSince Metis TechBio is not listed on Gulf exchanges, investors interested in biotech catalysts should watch for clinical trial milestones for MTS-128 or additional licensing announcements. The deal underscores the potential of small-cap biotech firms in Asia and may spur broader investor attention to the sector.